Recursion Pharmaceuticals Stock (NASDAQ: RXRX)

Recursion Pharmaceuticals

RECURSION PHARMACEUTICALS-A

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Fiserv,Office,In,Brookfield,,Wisconsin,,Usa,-,May,3,,2023.

News

Markets

Media

Trading Ideas

First Trust Advantage Preferred Income Fund

RGTI

RXRX

SMCI

Fiserv recently completed its acquisition of Payfare Inc. On &#34;Mad Money Lightning Round,&#34; Jim Cramer called it &#34;one of the greatest fintechs.&#34;

Jim Cramer: Fiserv Is &#39;One Of The Greatest Fintechs,&#39; Calls This Tech Company A Meme Stock

Cathie Wood's Buys The Dip In Tempus AI, Coinbase But Sells Ark's Bitcoin ETF Shares Amid Crypto Meltdown

Equities

Tech

ETFs

ABSI

ARKF

ARKK

ARKQ

ARKW

IBTA

PATH

PSNL

RBLX

ROKU

Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX.

Cathie Wood-Led Ark Invest Offloads Roblox, Roku, UiPath As Markets Take A Dip

biotech shutter

Analyst Color

Reiteration

Analyst Ratings

Movers

Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future revenue, according to Needham.

Recursion Pharmaceuticals&#39; Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals Inc

Press Releases

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Small Cap

Opinion

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Health Care

Economics

Altitude Lab Startups Raise $154M in Capital

Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City

Earnings

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Management

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

Recursion to Participate in Upcoming Investor Conference

AVAI

BFLY

DVAX

TDOC

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Apogee Therapeutics

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Beam Therapeutics

Biohaven

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Denali Therapeutics

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

ImmunityBio

Immunovant

Disc Medicine

Janux Therapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Kymera Therapeutics

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

Viking Therapeutics

Leerink Partners

Needham

Keybanc

Jefferies

JP Morgan

Comments

Recursion Pharmaceuticals

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga